{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:33:24Z","timestamp":1793144004547,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008376","name":"HUS Group","doi-asserted-by":"publisher","award":["TYH2020302"],"award-info":[{"award-number":["TYH2020302"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"publisher","award":["WBS4708719"],"award-info":[{"award-number":["WBS4708719"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ygyno.2025.04.589","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:15:37Z","timestamp":1746054937000},"page":"96-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer"],"prefix":"10.1016","volume":"197","author":[{"given":"Mikko","family":"Loukovaara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Pasanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.04.589_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2024.06.016","article-title":"The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup","volume":"189","author":"Aro","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0015","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","article-title":"Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer \u2013 a pooled analysis of PORTEC 1 and 2 trials","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0035","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0040","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer \u2014 combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0045","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/s41379-022-01165-w","article-title":"Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification","volume":"35","author":"Thompson","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242733","article-title":"Clinical factors as prognostic variables among molecular subgroups of endometrial cancer","volume":"15","author":"Kolehmainen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.5608","article-title":"Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis","volume":"253","author":"Huvila","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0065","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0070","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2024.10.028","article-title":"Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer","volume":"192","author":"Vrede","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0080","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0085","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cam4.3691","article-title":"Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer","volume":"10","author":"Loukovaara","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0090","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"L\u00e9on-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0095","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.23.00062","article-title":"Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer","volume":"27","author":"Horeweg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.23.00470","article-title":"Redefining the position of hormonal therapy in endometrial cancer in the era of molecular classification","volume":"42","author":"Pijnenborg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0105","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/IGC.0000000000000801","article-title":"L1 cell adhesion molecule as a predictor of disease-specific survival and patterns of relapse in endometrial cancer","volume":"26","author":"Pasanen","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0110","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0125","series-title":"Female Genital Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0130","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/jnci\/djt144","article-title":"L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation","volume":"105","author":"Zeimet","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0135","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ygyno.2024.01.046","article-title":"Prognostic value of three-tiered scoring system for lymph-vascular space invasion in endometrial cancer: a systematic review and meta-analysis","volume":"184","author":"Han","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2024.06.009","article-title":"The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma","volume":"188","author":"Bhatnagar","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0150","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/ijgc-2024-005746","article-title":"Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study","volume":"34","author":"Dagher","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0155","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/AOG.0b013e3181f39849","article-title":"Comparative performance of the 2009 International Federation of Gynecology and Obstetrics\u2019 staging system for uterine corpus cancer","volume":"116","author":"Lewin","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100048","article-title":"Clinicopathological stratification demonstrates survival differences between endometrial carcinomas with mismatch repair deficiency and no specific molecular profile: a cohort study","volume":"35","author":"Loukovaara","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.589_bb0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.589_bb0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ygyno.2017.03.017","article-title":"Surgical-pathological findings in type 1 and 2 endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study on GOG-210 protocol","volume":"145","author":"Creasman","year":"2017","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:08:00Z","timestamp":1791983280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"alternative-id":["S0090825825008157"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.589","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}